Agendia, Agilent expand breast cancer pact
This article was originally published in Clinica
Executive Summary
Dutch gene expression specialist Agendia is set to work more closely with its assay component supplier Agilent Technologies in a bid to develop new in vitro diagnostic tests for cancer. The deal, of which financial details were not disclosed, will see Santa Clara, California-based Agilent work with Agendia on the R&D and commercialisation of the new cancer test, as opposed to just being a supplier. Agendia and Agilent will provide each other with access to information about their research into genetic biomarkers.